Stable formulations of
View Patent ↗The present invention relates to stable formulations of Neisseria meningitis rLP2086 Subfamily B Antigens in immunogenic compositions. The present invention also relates to methods of preserving the conformation of Neisseria meningitis rLP2086 Antigens and methods for determining the potency of Neisseria meningitis rLP2086 antigens.
1. An immunogenic composition consisting essentially of 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) Subfamily B polypeptide; Polysorbate 80, wherein the molar ratio of the Polysorbate 80 to the polypeptide is 2.8:1; 0.5 mg/mL aluminum as aluminum phosphate; 10 mM histidine at a pH of 6.0; and 150 mM sodium chloride.
2. An immunogenic composition consisting essentially of 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) Subfamily B polypeptide; 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) Subfamily A polypeptide; Polysorbate 80, wherein the molar ratio of the Polysorbate 80 to the polypeptide is 2.8:1; 0.5 mg/mL aluminum as aluminum phosphate; 10 mM histidine at a pH of 6.0; and 150 mM sodium chloride.
3. An immunogenic composition consisting essentially of 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) Subfamily B polypeptide; Polysorbate 80, wherein the molar ratio of the Polysorbate 80 to the polypeptide is 2.8:1; 0.5 mg/mL aluminum as aluminum phosphate; 5 mM succinate at a pH 6.0; and 150 mM sodium chloride.
4. An immunogenic composition consisting essentially of 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) subfamily B polypeptide; 120 μg/mL of a purified lipidated Neisseria meningitidis serogroup B LP2086 (fHBP) Subfamily A polypeptide; Polysorbate 80, wherein the molar ratio of the Polysorbate 80 to the polypeptide is 2.8:1; 0.5 mg/mL aluminum as aluminum phosphate; 5 mM succinate at a pH of 6.0; and 150 mM sodium chloride.